Unilife and Sanofi announce a pharma partnership for $50 million.
Unilife announced the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years.
Additionally the agreement will allow Sanofi to make Unilife's wearable injectors available to its partners for use with applicable molecules under joint collaborations.
Unilife has granted Sanofi non-exclusive access to its wearable injector technology during the agreement.
Unilife maintains the right to enter into supply agreements with other pharmaceutical companies for the use of its wearable injectors, so long as Sanofi's non-exclusive access is preserved.
Sanofi also has the option to extend the agreement for additional periods.
In addition to an upfront payment and device sales, Unilife anticipates it will receive approximately $50 million from customization programs relating to Sanofi molecules and indications.
Additional revenue is also expected from customization programs conducted under joint collaborations with Sanofi partners.
Unilife will begin to generate revenue from Sanofi this fiscal year from an upfront payment, customization programs and initial commercial sales of the devices to Sanofi.
Unilife and Sanofi will also collaborate in the development of other new technologies that address additional unmet or emerging needs for the delivery of large dose volume biologics.
Additional information will remain confidential at this time.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Sanofi
Report: Partnering Deals and Alliances with Big Biotech
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity